OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
NCT07406217
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
256
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Immunodeficiency
Interventions
DRUG:
Paxlovid 5 days
DRUG:
Paxlovid 10 days
Sponsor
Calmy Alexandra
Collaborators
[object Object]